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Nicotine, the active compound in cigarettes, was considered as the risk factor for type 2 diabetes
mellitus (T2DM). In the human body, nicotine would be metabolized by the enzyme cytochrome
P450 2A6 (CYP2A6). CYP2A6 was known to be highly polymorphic. The active form of this
gene was CYP2A6 *1, while the CYP2A6 *4 and CYP2A *9 alleles were the inactive alleles. The
presence of this inactive allele caused the decreased activity of CYP2A6 so that it would affect the
level of nicotine in the blood and would eventually cause an increased blood sugar levels. This
study aimed to determine the effect of CYP2A6 polymorphism on glycohemoglobine levels among
Javanese smokers. The blood sugar levels were measured by hemoglobin A1c (HbA1c). In this study,
33 active smokers involved in the study were identified as slow metabolizers, by which 63.9% of all
test participants had CYP2A6 *1/*4 genotype and as many as 6.1% of the test participants had the
CYP2A6 *1/*4/*9. The HbA1c levels among the participants have been analyzed, 28 participants
were in normal range (4.83-5.56%); 4 participants were identified in prediabetes condition (5.70%
- 5.97%) and 1 participant was in diabetes with HbA1c level was 7.16%. This condition indicates
that the presence of CYP2A6 *4 and *9 alleles will affect HbA1c levels which can eventually lead
to T2DM disease.
Keywords: polymorphism; CYP2A6*4; CYP2A6 *9; glycohemoglobine

INTRODUCTION
Diabetes, one of the underdiagnosed diseases, has been
a serious threat to public health. The uncontrolled blood
sugar could have been associated with cardiovascular
diseases and blood pressure, development of renal
(kidney) complications, nephropathy, retinopathy and
foot ulcer. In some cases, by the time diabetes was
diagnosed, the complications of diabetes might already
be present (Buell et al., 2007). IDF Diabetes Atlas 8th
Edition (International Diabetes Federation, 2017) was
estimated that 82 million adults aged 20-79 years were
living with diabetes in the South East Asia Region in
2017, representing a regional prevalence of 8.5%. About
45.8% of these diabetes cases were undiagnosed.
As of 2017, Indonesia was the world’s top ten countries
suffering from diabetes including China, India, United
State, Brazil and Mexico. Approximately, 10 million
people had diabetes in this country (International
Diabetes Federation, 2017). Close to half (48.8%) of
all adults with diabetes in the region live in urban areas.
More than 1 in 4 of them were not aware they had the
disease. It was estimated that there are 50% of people
with undiagnosed diabetes in Indonesia. Despite being
largely preventable, type 2 diabetes (T2DM) accounts
for more than 90% of all diabetes cases (Soelistijo et al.,
2015).
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In 2010, American Diabetes Association (ADA) had
recommended the use of the Hemoglobin (HbA1c) test
to diagnose diabetes (American Diabetes Association,
2011). HbA1c tests measure average blood glucose
over the past two to three months. The HbA1c test is
being used for diagnosis of T2DM and prediabetes.
A normal HbA1c level is 5.6 percent or below and a
level of 5.7 to 6.4 percent indicates prediabetes, while
people with diabetes have an HbA1c level at 6.5 percent
or above (American Diabetes Association, 2010; The
International Expert Committee, 2009).
T2DM is associated with modifiable lifestyle risk
factors. Smoking had raised levels of HbA1 in smokers
which had been known as the factor causing T2DM.
Smokers are 30-40% more likely to develop T2DM than
nonsmokers (Nilsson et al., 2004; Vlassopoulos et al.,
2013; Xie et al., 2009). Nicotine, the main compound
of cigarettes that causes addiction, had been proposed
to be involved in the development of T2DM (Bajaj,
2012; Borowitz & Isom, 2008; Xie et al., 2009). It had
been proven that nicotine to be a risk factor for insulin
resistance and also induced apoptosis of beta cells which
caused decreasing insulin in blood and eventually could
lead to higher blood glucose levels (Bergman et al.,
2012; Houston et al., 2006; Willi et al., 2007; Xu et al.,
2012).

Genetic Polymorphism of Cytochrome

Nicotine is primarily metabolized in the liver by
cytochrome P450 enzymes (CYP2A6). CYP2A6 shows
great interindividual and interethnic variations in its
expression levels and conversion activities, which are
mainly attributed to CYP2A6 genetic polymorphisms.
Genetic variation in the CYP2A6 gene could increase or
decrease enzyme activity through altering the protein’s
expression level or its structure and function (Hukkanen
et al., 2005). The CYP2A6*1, a common CYP2A6 allele,
was considered as fast metabolizer, while any other
alleles, CYP2A6*4 and CYP2A6*9, were associated
with slower metabolizers (Raunio & Rahnasto-Rilla,
2012). According to Liu et al. (2011), heavy smoking
may increase the risk of T2DM-particularly in smokers
with CYP2A6 poor metabolizer genotypes.
This study was the first one of its kinds conducted in
Indonesia which aimed to find out the relations between
genetic polymorphisms, primarily CYP2A6*4 and
CYP2A6*9 alleles, and hemoglobin among Javanese
Indonesian smokers. By knowing these predictive
relationships that show us how prediabetes occurs, we
hopefully can strive for an appropriate and adequate
prevention. Besides, we can also determine the needed
screening data, to detect prediabetes early before it
develops to become diabetes. This research was also
expected to support government programs to reduce the
number of smokers in Indonesia.
METHODS
The study was performed from August 2016 to July
2017 using a cross-sectional design and was performed
in 33 healthy male participants as they were not taking
any medications. The participants were recruited from
Sanata Dharma University’s employees which had
three or more Javanese grandparents. Participants were
20 to 45 years of age and were defined as a current
regular smoker, who smoked at least one cigarette
per day and smoked more than 100 cigarettes during
his lifetime at the time of interview. According to the
number of cigarettes smoked per day, participants were
classified as light smokers (cigarettes a day/CPD < 10),
moderate smokers (CPD 11-20) and heavy smokers
(CPD > 20). They had been given informed consent
sheet prior to participating in this study. Original ethical
approval for the Laboratory Research was granted
by the Ethics Committees of Medical Research Duta
Wacana University No. 424/C.16/FK/2017 (Yogyakarta,
Indonesia).
Blood samples were collected from a cubital vein just
before genotyping of CYP2A6 and HbA1c analysis.
Genomic DNA was prepared using Ron’s Blood and
Cell DNA Mini Kit (Bioron-GmbH). The genotyping
of CYP2A6*1, CYP2A6*4 and CYP2A6*9 alleles was
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previously assessed using primer-specific Polymerase
Chain Reaction in our laboratory (Patramurti et al.,
2015; Patramurti, 2017). The primer forward: 2A6-B6
(3’-CCT CAT CAC ACA CAA CTT CCT C-5’) and
primer reverse: 2A6-UTRAS1 (5’-TGT AAA ATG
GGC ATG AAC GCC C-3’) were used to identify allele
CYP2A6*1 and CYP2A6*4, while the other primer
(5’-GATTCCTCTCCCCTGGAAC-3’ (primer forward)
and 5’-GGCTGGGGTGGTTTGCCTTT A-3’ (primer
reverse) were used to identify allele CYP2A6*9. A
total HbA1c analysis was performed by NORUDIA® N
HbA1c in the Clinical Pathology Laboratory, Bethesda
Hospital Yogyakarta using the Architect 600 instrument,
which was calibrated using Diabetes Control and
Complications Trial (DCCT) standards with coefficient
of variation < 2.5%.
To describe the study population, we used Microsoft
Excel 2016 in which we calculated the mean and standard
of deviation of each continuous quantitative variable and
the percentage for the genes. The qualitative analysis was
used to illustrate the effect of CPY2A6 polymorphism,
CYP2A6*1, CYP2A6*4 and CYP2A6*9 alleles, on
HbA1c levels.
RESULTS AND DISCUSSION
Various studies reported the associations between
smoking and CYP2A6 genotypes in the development
of some cancer (Boffetta, 2008; Hecht, 2012; Mallery
et al., 2014; Shields, 2002). Other studies suggested
that smokers with defective CYP2A6 alleles are at a
higher risk of developing T2DM (Liu et al., 2011).
Here, we evaluated the influence of CYP2A6 genotypes
on T2DM in Javanese Indonesian smokers based on a
cross-sectional study, after controlling for age, gender,
and family history of diabetes.
There were 33 male Javanese Indonesian smokers
participating in this study. The average of the
participants’ age was 34.3 ± 9.3 years. Three alleles were
identified using a PCR method among the participants,
they were CYP2A6*1 (an active allele), CYP2A6*4 and
CYP2A6*9. The *4 and *9 alleles are more common
allele in Asian populations than in people of European
ancestry. CYP2A6*4 allele is a gene deletion, leading
for most poor metabolizers in Asians (Nakajima et al.,
2004; Yusof & Gan, 2009). CYP2A6*9 allele is a single
nucleotide polymorphisms (SNPs) which has a −48T to
G nucleotide substitution in the TATA box (a sequence of
DNA found in the core promoter region of genes) of the
5′-flanking region of the CYP2A6, which is in the TATA
box of the CYP2A6 promoter region. The substitution
decreases CYP2A6 mRNA expression and subsequently
lowers enzyme activity (Pitarque, 2001).
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Table 1. Allele frequencies of CYP2A6*1, CYP2A6*4, CYP2A6*9
and genotype among Javanese smokers
Allele

Frequency (n=68)

Total

CPD < 10 (n=20)

CPD 11-20 (n=13)

CYP2A6*1

29.4% (20)

19.1% (13)

48.5% (33)

CYP2A6*4

29.4% (20)

19.1% (13)

48.5% (33)

CYP2A6*9

3 % (2)

3% (2)

Genotipe

0
Frequency (n=33)

CYP2A6*1/*1

0% (0)

0% (0)

0% (0)

CYP2A6*1/*4

60.6% (20)

33.3% (11)

93.9% (31)

CYP2A6*1/*9

0% (0)

0% (0)

0% (0)

CYP2A6*1/*4/*9

0% (0)

6.1% (2)

6.1% (2)

CYP2A6*4/*4

0% (0)

0% (0)

0% (0)

CYP2A6*4/*9

0% (0)

0% (0)

0% (0)

CYP2A6*9/*9

0% (0)

0% (0)

0% (0)

Total

According to genotype analysis, smokers were classified
as normal metabolizer (100% CYP2A6 activity),
intermediate metabolizer (individuals hypothesized to
have approximately 75% of normal activity), and slow
metabolizer (individuals hypothesized to have 50% or
less of the normal activity). Smokers who did not have
any copies of CYP2A6*4 or CYP2A6*9 were classified
as ‘normal metabolizer’ (i.e. *1/*1). Smokers who had
only CYP2A6*9 allele were classified as ‘intermediate
metabolizers’ (e.g. *1/*9). The ‘slow metabolizer’ group
refers to smokers who had either CYP2A6*4 allele or
two CYP2A6*9 alleles (e.g. *1/*4 or *9/*9) and the
‘poor metabolizers’ were indicated as smokers who
had either CYP2A6*4 and CYP2A6*9 allele or two
CYP2A6*4 alleles (e.g. *9/*4, or *4/*4) (Mwenifumbo
et al., 2008; Mwenifumbo et al., 2007; Schoedel et al.,
2004).

null CYP2A6 alleles do smoke less (Ando et al., 2003;
Fujieda et al., 2004; Liu, David, et al., 2011; Minematsu
et al., 2006; Schoedel et al., 2004; Rao et al., 2000).

In the present study, we found that all of the 33
participants involved in the study had heterozygous
alleles and none of the participant had homozygous
CYP2A6*1. There are 93.9% participant had CYP2A6
* 1/*4 genotype and 6.1% had CYP2A6 * 1/*4/*9
genotype (Table 1). Based on this result, all participants
were identified as slow metabolizers. According to the
number of cigarettes per day, participants were classified
into three levels, light smokers (CPD < 10), moderate
smokers (CPD 11-20) and heavy smokers (CPD >
20). The participants involved in this study were only
classified as light smokers (17) and moderate smokers
(15). None of the participants were classified as heavy
smokers, so this study was in line with numerous studies
that had reported smokers who carry reduced activity or

and would have impact on risk of T2DM in smokers.
Variation in the CYP2A6 gene could decrease the rate
of nicotine metabolic-inactivation, therefore smokers
with slow or poor metabolizer genotypes, whose CPD
was more than 20, were more likely to saturate this
metabolism pathway, resulting to higher nicotine plasma
levels. These slow metabolizers would then be more
likely to develop T2DM due to their higher level of
nicotine in blood (Bajaj, 2012; Borowitz & Isom, 2008;
Xie et al., 2009). Some studies suggested that nicotine
either could have toxic effect on the pancreatic beta
cells, or causing insulin resistance that leading to high
risk of T2DM (Bajaj, 2012; Bergman et al., 2012; Xu
et al., 2012). Some other studies reported that smoking
would increase the HbA1c level (Nilsson et al., 2004;
Vlassopoulos et al., 2013).
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About 70 to 80% of inhaled nicotine was converted
to cotinine by the CYP2A6 enzyme; cotinine was
further oxidized into trans-3-hydroxycotinine by this
enzyme and all three compounds were excreted in urine
(Hukkanen et al., 2005) (Figure 1).
Metabolism of nicotine had associations for addiction

Figure 1. Primary metabolism pathway of nicotine
facilitated by CYP2A6
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Figure 2. Distribution of HbA1c levels among Javanese Indonesian smokers
based on smoking duration (year)
Results of our study showed that HbA1c levels among
participants were ranging from 4,83-7,16% with an
average of 5.27 and SD of 0.427. Based on our results,
almost all participants had a normal HbA1c level, four
participants were on prediabetes condition and only
one participant was identified suffering diabetes. The
prediabetes condition mean that smokers might have a
higher chance of getting diabetes, depending on level
of hemoglobin A1c and presence of other risk factors,
such as obesity and family history (American Diabetes
Association, 2010).
None of the participants involved in this study was
classified as heavy smoker and all of them were identified
as slow metabolizers. This result was consistent with
Liu et al. (2011) which demonstrated that the risk of
T2DM was higher in heavy smokers who have slow
or poor metabolizer genotypes rather than in light or
intermediate smokers with slow or normal metabolizers.
The participants who had HbA1c level more than 5.7%
(prediabetes and diabetic conditions) were observed
in individuals who smoke cigarettes for more than 25
years (Figure 2). These results support other studies that
reveal chronic smokers with slow and poor metabolizer
genotypes would have high risk of T2DM caused by the
pancreas exposed to greater circulating levels of nicotine
that might contribute to apoptosis of islet β-cells and
furthermore decreasing insulin secretion (Jyothirmayi et
al., 2013).
Any other compounds, pre-carcinogens, found in tobacco
smoke, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)1-butanol (NNAL); N-nitrosodiethylamine (NDEA),
could be activated to carcinogens by CYP2A6 in liver
or CYP2E1 expressed in pancreatic islets (Anttila et
al., 2011; Brown et al., 2007; Hecht, 2003; Wang et al.,

2012). Therefore, smokers with CYP2A6 slow or poor
metabolizing genotype, the hepatic first-pass clearance of
these compounds might be decreased lead to increasing
systemic levels of these pre-carcinogens and more
exposure of other organs, such as pancreas. Ultimately,
the higher levels of nitrosamines in pancreatic islet cells
will cause metabolic activation by CYP2E1, which
lead to pancreatic inflammation and apoptosis of islet
β-cells, followed by the reducing insulin secretion and
consequently the increasing risk of incident T2DM.
Most previous experimental and clinical studies described
that nicotine decreased insulin sensitivity. Bergman et al.
(2009) revealed that chronic cigarette smokers were less
insulin sensitive compared with control subjects that did
not smoke. Furthermore, Bergman et al. (2012) had found
that nicotine could increase mTOR/p70S6 K activity in
cultured L6 myotubes in relation with increased IRS-1
Ser 636 phosphorylation and induced insulin resistance
in skeletal muscle which subsequently reduced insulinstimulated glucose uptake.
This study supports the hypothesis that the blood
glucose levels might be increased in smokers, who may
have high risk to diabetes mellitus, if smoking is not
controlled. Furthermore, our study also supports many
previous studies that CYP2A6 polymorphism, primarily
caused by defective alleles (*4 and *9), would be a
factor of high risk on T2DM. These findings suggest that
chronic smokers whose genotype as slow metabolizer
would enhance the development of T2DM. It induces the
reduction of insulin secretion caused by the toxic effect
of nicotine or nitrosamine compound to the pancreas
as well as the occurrence of insulin resistance. Finally,
the results expand the understanding to the possibility
effects of cigarette smoking on T2DM. It may have
major public health consequences for tobacco control
E-ISSN 2477-0612
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and efforts to prevent the development of diabetes in
Indonesia, especially to the Javanese smokers.
CONCLUSION
Diabetes mellitus is one of serious problem on public
health that many people are unaware of suffering this
disease. Diabetes in Indonesia, mostly T2DM caused
by lifestyle, is growing precipitously. Smoking, another
public health problem encountered in Indonesia, is one
of lifestyle factors that causes diabetes. Chronic smokers,
either light or intermediate smokers, whose genotypes
were classified as slow and poor metabolizers, would
have high risk of suffering T2DM.
The most important limitations of this study that other
factors have not been investigated. They might be
confounding to our results, for example obesity, physical
activity, dietary factors and biochemical variation such
as plasma nicotine levels or total urinary nicotine
equivalents.
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